• Overview
  • Eligibility
  • More info
  • Locations

pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress (NCT03028675)

Twenty subjects (10 patients and 10 age-matched control volunteers) will be recruited for this study. MRI scans will take place on a 3T MRI Scanner (Skyra or Prisma, Siemens Medical Solutions) located at The NYU Center for Biomedical Imaging. MRI scans will consist of a 1-hour brain scan for both patients and controls. In the first 6 months of the study, investigators will develop and test a uMT-based APT imaging for brain tissue pH measurement and use a hypercapnia paradigm to validate the tissue pH changes between breathing room air and 5% CO2 (by increasing tissue acidity) inhalation. With implementation of hypercapnia MRI, pH-weighted imaging will be validated for its robustness and reproducibility.
  • Drug: Gd-DTPA-ST
    The contrast agent (Gd-DTPA, Gadavist) will be injected intravenously (IV) in the arm (patients only). The
    • Gadavist
  • Drug: Control
    No Contrast Agent
    Ages eligible for Study
    18 Years to 65 Years
    Genders eligible for Study
    All
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Inclusion Criteria:
    • Healthy male or female non-MS control volunteers
    Exclusion Criteria:
    • Medically unstable or with cardiac, pulmonary, hematological, renal, or hepatic dysfunction.
    • Current or past DSM-IV diagnosis of major depression, bipolar and psychotic disorders.
    • Contraindications for MRI, including
    • Intracranial clips
    • Metal implants
    • External metallic devices/objects/clips within 10mm of the head
    • Suspected or confirmed metal in the eyes (history of welding or similar activity)
    • Claustrophobia
    • Cardiac pacemaker or pacing wires
    • Pregnancy - Pregnancy tests will be offered to women of childbearing age at no cost to the subject
    • History of moderate to severe head injury, stroke, and seizures.
    • Alcoholism or drug dependency.
    • Renal or liver disease as this may cause concerns related to Gd-DTPA contrast agent.
    • Allergy to the contrast agent Gadolinium
    • Relapses or steroid therapy in patient at or in the month preceding the study
    • Patients only
    The contrast agent (Gd-DTPA, Gadavist) will be injected intravenously (IV) in the arm (patients only). The IV will be inserted by qualified medical professional at CBI. This contrast agent will be standard dose in accordance with its FDA approved labeling and dosing. Controls will NOT be administered the contrast agent.

    1 locations

    United States (1)
    • New York University School of Medicine
      recruiting
      New York, New York, United States, 10016
    Status:
    recruiting
    Type:
    Interventional
    Phase:
    Start:
    30 April, 2017
    Updated:
    12 July, 2017
    Participants:
    20
    Apply
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!